GO:0120559 phosphatidylethanolamine lysophospholipase A1 activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0120559 describes the hydrolysis of 1-acyl-sn-glycero-3-phosphoethanolamine to sn-glycero-3-phosphoethanolamine, a fatty acid, and a proton.
• This activity is a lysophospholipase A1-type reaction that removes the sn-1 acyl chain from phosphatidylethanolamine (PE) lysophospholipids.
• Enzymes with this activity have been identified in bacteria, such as Leptospira biflexa, and in mammalian tissues including brain and myocardium.
• The reaction contributes to phospholipid catabolism and membrane remodeling, and its products can influence cellular signaling.
• Dysregulation of lysophospholipase activity has been linked to phospholipid accumulation disorders such as mucolipidosis IV.
• Studying GO:0120559 requires combining lipidomics, enzyme assays, and CRISPR-based gene editing to dissect gene function.
Description
Phosphatidylethanolamine lysophospholipase A1 activity (GO:0120559) is a molecular function that catalyzes the hydrolysis of a 1-acyl-sn-glycero-3-phosphoethanolamine (a lysophosphatidylethanolamine, LPE) to sn-glycero-3-phosphoethanolamine, a free fatty acid, and a proton. This activity is a type of lysophospholipase A1 reaction, meaning it specifically cleaves the acyl ester bond at the sn-1 position of the glycerol backbone. The reaction is part of the broader phospholipid catabolic network that maintains membrane lipid homeostasis and generates lipid mediators. Researchers study this activity because it sits at the intersection of phospholipid metabolism, membrane remodeling, and signaling, and because its dysregulation has been associated with metabolic and neurodegenerative disorders. The enzyme activity has been detected in diverse organisms, from the spirochete Leptospira biflexa to mammalian brain and heart tissues. Understanding its catalytic mechanism and regulation is essential for mapping lipid metabolic pathways and for developing therapeutic strategies that target lipid-processing enzymes.
phosphatidylethanolamine lysophospholipase A1 activity At A Glance
| GO ID | GO:0120559 |
|---|---|
| GO term | phosphatidylethanolamine lysophospholipase A1 activity |
| Ontology | molecular_function |
| Synonym | phosphatidylethanolamine lysophospholipase A1-type activity; phosphatidylethanolamine lysophospholipase activity |
| Definition | Catalysis of the reaction: a 1-acyl-sn-glycero-3-phosphoethanolamine + H2O = sn-glycero-3-phosphoethanolamine + a fatty acid + H+ |
| Major function | Hydrolysis of lysophosphatidylethanolamine at the sn-1 position to release a fatty acid and glycerophosphoethanolamine |
| Substrate | 1-acyl-sn-glycero-3-phosphoethanolamine (lysophosphatidylethanolamine) |
| Products | sn-glycero-3-phosphoethanolamine, a fatty acid, and H+ |
| Cellular context | Membrane-associated lipid catabolism; detected in brain, myocardium, and bacteria |
What Is GO:0120559?
GO:0120559 is defined as the catalysis of the reaction: a 1-acyl-sn-glycero-3-phosphoethanolamine + H2O = sn-glycero-3-phosphoethanolamine + a fatty acid + H+. In other words, it is an enzyme activity that removes the fatty acid attached to the sn-1 position of a lysophosphatidylethanolamine molecule, using water to break the ester bond and releasing a free fatty acid and a proton. This is a lysophospholipase A1-type activity because it acts on a lysophospholipid substrate and cleaves the acyl chain at the sn-1 position.
Why Is phosphatidylethanolamine lysophospholipase A1 activity Important in Cell Biology?
GO:0120559 is important because it represents a specific enzymatic step in phospholipid catabolism that controls the cellular levels of lysophosphatidylethanolamine and its downstream metabolites. These lipid species are not merely structural; they can act as signaling molecules and can modulate the activity of other phospholipases. The activity has been detected in mammalian tissues such as brain and heart, where membrane lipid remodeling is critical for normal function. In bacteria, lysophospholipase A1 activity contributes to membrane turnover and pathogenesis. Moreover, defects in phospholipid catabolism are linked to lysosomal storage disorders and neurodegeneration, making this activity a potential therapeutic target. Studying GO:0120559 helps researchers understand how cells maintain lipid homeostasis and how this process goes awry in disease.
• Maintains membrane lipid homeostasis by removing lysophospholipids that can destabilize membranes.
• Generates fatty acids and glycerophosphoethanolamine for further metabolic use.
• Modulates signaling lipids that influence brain phospholipid catabolism.
• Contributes to myocardial phospholipid metabolism and membrane integrity.
• Plays a role in bacterial membrane remodeling and host-pathogen interactions.
• Its dysfunction is associated with phospholipid accumulation in mucolipidosis IV.
• Provides a target for studying lysophospholipase A1-type enzymes in humans.
• Helps define the substrate specificity of phospholipase A1 family members.
• Can be regulated by local anaesthetics and other membrane-active compounds.
• Offers a biochemical marker for lipid metabolic disorders and neurodegeneration.
Molecular Mechanism of phosphatidylethanolamine lysophospholipase A1 activity
Substrate recognition and binding
In simple terms: The enzyme first grabs a lysophosphatidylethanolamine molecule and holds it in place.
The enzyme binds a 1-acyl-sn-glycero-3-phosphoethanolamine substrate, positioning the sn-1 acyl chain into the active site. This binding is selective for lysophospholipids with a free sn-2 hydroxyl and a phosphoethanolamine headgroup. The substrate is typically generated by phospholipase A2 or other lipases that remove the sn-2 acyl chain from phosphatidylethanolamine.
Catalytic hydrolysis
In simple terms: Water is used to cut the fatty acid off the glycerol backbone.
A water molecule attacks the ester bond at the sn-1 position, leading to the release of a free fatty acid and the formation of sn-glycero-3-phosphoethanolamine. The reaction also produces a proton, consistent with the GO definition. This hydrolysis is characteristic of lysophospholipase A1-type activity, which specifically cleaves the sn-1 acyl ester.
Product release and membrane dynamics
In simple terms: The products are released and can be used elsewhere or affect the membrane.
After catalysis, the fatty acid and glycerophosphoethanolamine are released from the active site. These products can be further metabolized or can act as signaling molecules. The removal of lysophosphatidylethanolamine from membranes helps maintain membrane stability and prevents the accumulation of detergent-like lysolipids.
Regulation by local environment
In simple terms: The enzyme's activity can be turned up or down by molecules around it.
Local anaesthetics and other membrane-active agents have been shown to affect phospholipase activities, including lysophospholipase. Additionally, phosphatidylcholine and phosphatidylethanolamine metabolites can inhibit lysophospholipase activity in brain, suggesting feedback regulation. The activity may also be influenced by the lipid composition of the membrane and the presence of cofactors.
Key Genes Involved in GO:0120559 phosphatidylethanolamine lysophospholipase A1 activity
The following genes and proteins are associated with phosphatidylethanolamine lysophospholipase A1 activity or related lysophospholipase functions, based on published biochemical and genetic studies.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PS-PLA1 (PLA1A) | Phosphatidylserine-specific phospholipase A1 with lysophospholipase activity | Alternative splicing yields an isoform with lysophosphatidylserine-specific lysophospholipase activity |
| LPLA1 (bacterial) | Lysophospholipase A1 in Leptospira biflexa | Demonstrates presence of phospholipase A1 and lysophospholipase in spirochetes |
| PLA2G6 | Phospholipase A2, generates lysophospholipids | Provides substrates for lysophospholipase A1 activity |
| PLA2G4A | Cytosolic phospholipase A2 | Contributes to lysophospholipid production in brain |
| LPCAT1 | Lysophosphatidylcholine acyltransferase | Balances lysophospholipid levels |
| ABHD12 | Lysophosphatidylserine lipase | Related lysophospholipase with neurological relevance |
| ABHD6 | Lysophospholipase involved in endocannabinoid metabolism | May share substrate overlap with lysophospholipases |
| NAPEPLD | N-acyl phosphatidylethanolamine phospholipase D | Links phosphatidylethanolamine metabolism to N-acylethanolamine biosynthesis |
| PLA2G15 | Lysosomal phospholipase A2 | Contributes to phospholipid catabolism in lysosomes |
| MCOLN1 | Mucolipin 1, lysosomal cation channel | Mutations cause mucolipidosis IV with phospholipid accumulation |
| SQSTM1 | Autophagy receptor | Post-translational modifications affect autophagy and neurodegeneration |
| PLA1A (isoform 2) | Lysophospholipase A1-type enzyme | Exhibits lysophosphatidylserine-specific lysophospholipase activity |
| LPLA1 (myocardial) | Myocardial lysophospholipase | Detected in heart tissue, involved in phospholipid catabolism |
| LPLA1 (brain) | Brain lysophospholipase | Regulated by phospholipid metabolites |
| LPLA1 (Leptospira) | Bacterial lysophospholipase A1 | Potential virulence factor in Leptospira |
| PLA2G6 (iPLA2β) | Calcium-independent phospholipase A2 | Generates lysophospholipids for lysophospholipase action |
| LPGAT1 | Lysophosphatidylglycerol acyltransferase | Remodels lysophospholipids |
| MBOAT7 | Lysophosphatidylinositol acyltransferase | Affects lysophospholipid pools |
How Is phosphatidylethanolamine lysophospholipase A1 activity Regulated?
The activity of phosphatidylethanolamine lysophospholipase A1 can be regulated at multiple levels. Local anaesthetics have been shown to inhibit phospholipase activities, including lysophospholipase, suggesting direct modulation of enzyme activity. In brain, phosphatidylcholine and phosphatidylethanolamine metabolites inhibit lysophospholipase activity, indicating product feedback or membrane-mediated regulation. Additionally, post-translational modifications of autophagy-related proteins such as SQSTM1 can influence lipid metabolism and neurodegeneration, potentially affecting lysophospholipase pathways indirectly. The enzyme may also be regulated by its lipid environment and by the availability of its lysophospholipid substrate, which is produced by phospholipase A2 enzymes.
phosphatidylethanolamine lysophospholipase A1 activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MCOLN1 | Mucolipidosis IV with phospholipid accumulation | Patient fibroblasts or MCOLN1 knockout cells |
| SQSTM1 | Neurodegeneration and autophagy dysregulation | SQSTM1 knockout or point-mutation neurons |
| PLA1A | Lysophospholipid signaling in brain | PLA1A overexpression or knockout in neuronal cells |
| PLA2G6 | Neurodegeneration with brain iron accumulation | PLA2G6 knockout mouse or cell model |
| LPLA1 (bacterial) | Leptospira membrane remodeling | Leptospira biflexa lysophospholipase mutants |
Neurodegeneration and lipid metabolism
Dysregulation of phospholipid catabolism, including lysophospholipase activity, has been implicated in neurodegenerative processes. Phosphatidylcholine and phosphatidylethanolamine metabolites that inhibit lysophospholipase activity may contribute to altered brain phospholipid catabolism. Furthermore, post-translational modifications of SQSTM1 affect autophagy and neurodegeneration, linking lipid metabolism to protein degradation pathways.
Lysosomal storage disorders
Mucolipidosis IV is a lysosomal storage disorder characterized by phospholipid accumulation in cultured fibroblasts. Although the primary defect is in MCOLN1, the accumulation of phospholipids suggests that lysosomal phospholipid catabolism, including lysophospholipase A1 activity, may be impaired or overwhelmed. This makes the activity relevant to understanding the biochemical basis of the disease.
Cardiovascular and myocardial function
Phospholipases of the myocardium, including lysophospholipase, play roles in membrane remodeling and lipid signaling. Alterations in these activities could affect cardiac membrane integrity and function, although direct links to specific cardiovascular diseases require further study.
Bacterial pathogenesis
Leptospira biflexa possesses phospholipase A1 and lysophospholipase activities, which may contribute to membrane turnover and host interaction. These enzymes could serve as potential targets for antibacterial strategies, though their exact role in pathogenesis remains to be fully defined.
From phosphatidylethanolamine lysophospholipase A1 activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate lysophospholipase A1 gene alter cellular lipid composition? | CRISPR knockout cell line (e.g., HEK293, HeLa) followed by lipidomics |
| Does a specific point mutation in the catalytic site abolish enzyme activity? | CRISPR point-mutation knock-in of catalytic residue |
| Can a tagged version of the enzyme be used to track its localization? | Knock-in of fluorescent or epitope tag at the endogenous locus |
| Does overexpression of the enzyme change lysophosphatidylethanolamine levels? | Doxycycline-inducible overexpression cell line |
| Which genes regulate lysophospholipase A1 activity in a genome-wide screen? | CRISPR library screening with a lipid-based readout |
| Does the enzyme interact with specific membrane lipids? | Proximity labeling or co-immunoprecipitation in knockout background |
How to Study the phosphatidylethanolamine lysophospholipase A1 activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Lysophospholipase A1 activity assay | Enzyme activity using radiolabeled or fluorescent substrate | Kinetic characterization of purified or recombinant enzyme |
| Lipidomics (LC-MS/MS) | Levels of lysophosphatidylethanolamine and related lipids | Assessing cellular lipid changes after gene knockout |
| CRISPR knockout screening | Genes required for lysophospholipid homeostasis | Identifying novel regulators of the pathway |
| Fluorescence microscopy | Subcellular localization of tagged enzyme | Determining organelle targeting |
| Western blotting | Protein expression levels | Validating knockout or overexpression |
| qRT-PCR | mRNA expression of candidate genes | Measuring transcriptional regulation |
| Co-immunoprecipitation | Protein-protein interactions | Identifying binding partners |
| Thin-layer chromatography | Separation of lipid products | Confirming reaction products |
Enzymatic activity assays
Lysophospholipase A1 activity can be measured using radiolabeled or fluorescent lysophosphatidylethanolamine substrates, followed by separation of products by thin-layer chromatography or high-performance liquid chromatography. These assays allow determination of specific activity, substrate specificity, and kinetic parameters.
Lipidomics and mass spectrometry
Mass spectrometry-based lipidomics enables quantification of lysophosphatidylethanolamine and its metabolites in cells or tissues. This approach can reveal changes in lipid pools upon genetic manipulation of candidate genes. It is particularly useful for linking enzyme activity to cellular lipid homeostasis.
CRISPR-based genetic screens
Genome-wide CRISPR knockout or activation screens can identify genes that regulate lysophospholipase A1 activity or lysophospholipid levels. Such screens typically use a fluorescent lipid reporter or a phenotypic readout coupled with next-generation sequencing.
Imaging and subcellular localization
Fluorescence microscopy of tagged enzymes can reveal their subcellular localization and dynamics. Knock-in of a fluorescent tag at the endogenous locus allows visualization of the enzyme in its native context.
How CRISPR Can Be Used to Study GO:0120559 phosphatidylethanolamine lysophospholipase A1 activity
Knockout
CRISPR knockout of candidate lysophospholipase A1 genes (e.g., PLA1A, ABHD12) can be used to determine whether loss of function alters cellular lysophosphatidylethanolamine levels or lipid signaling. Knockout cell lines are generated by introducing frameshift mutations in early exons, followed by validation of protein loss by western blotting.
Point Mutation
CRISPR point mutation can be used to substitute catalytic residues (e.g., serine in the active site) to abolish enzyme activity without affecting protein expression. This approach helps distinguish catalytic activity from scaffolding functions.
Knock-in
Knock-in of a fluorescent or epitope tag at the endogenous locus allows tracking of the enzyme's localization and interaction partners in live cells. This is achieved by homology-directed repair using a donor template.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression can be used to increase enzyme levels, enabling studies of gain-of-function effects on lipid metabolism and membrane remodeling.
How EDITGENE Supports phosphatidylethanolamine lysophospholipase A1 activity Research
Researchers studying phosphatidylethanolamine lysophospholipase A1 activity-related genes often need to determine whether a candidate gene is causally involved in lipid metabolism, membrane remodeling, or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research, from gene knockout to precise point mutations and library screening.
Contact EDITGENE today to design your custom CRISPR model for phosphatidylethanolamine lysophospholipase A1 activity research.
Frequently Asked Questions About phosphatidylethanolamine lysophospholipase A1 activity
What is phosphatidylethanolamine lysophospholipase A1 activity?
It is an enzyme activity that removes the sn-1 fatty acid from lysophosphatidylethanolamine, producing glycerophosphoethanolamine, a free fatty acid, and a proton.
What is the GO ID for phosphatidylethanolamine lysophospholipase A1 activity?
The GO ID is GO:0120559.
What genes are involved in phosphatidylethanolamine lysophospholipase A1 activity?
Genes such as PLA1A, ABHD12, and bacterial lpla1 have been associated with lysophospholipase A1-type activities.
What is the reaction catalyzed by GO:0120559?
A 1-acyl-sn-glycero-3-phosphoethanolamine + H2O = sn-glycero-3-phosphoethanolamine + a fatty acid + H+.
Which diseases are linked to lysophospholipase A1 dysfunction?
Phospholipid accumulation disorders such as mucolipidosis IV and neurodegenerative conditions have been linked to altered phospholipid catabolism.
How can I study phosphatidylethanolamine lysophospholipase A1 activity?
Enzymatic assays with radiolabeled substrates, lipidomics, and CRISPR knockout models are common approaches.
What is the difference between phospholipase A1 and lysophospholipase A1?
Phospholipase A1 acts on diacyl phospholipids, while lysophospholipase A1 acts on monoacyl lysophospholipids, removing the remaining sn-1 acyl chain.
Is phosphatidylethanolamine lysophospholipase A1 activity found in bacteria?
Yes, it has been detected in Leptospira biflexa, where it may contribute to membrane remodeling.
Can local anaesthetics affect this activity?
Local anaesthetics have been shown to affect phospholipase activities, including lysophospholipase.
What model systems are used to study GO:0120559?
Cell lines, knockout mice, and bacterial models are used, often combined with lipidomics and enzyme assays.
Conclusion
Phosphatidylethanolamine lysophospholipase A1 activity (GO:0120559) is a specific lipid catabolic function that removes the sn-1 acyl chain from lysophosphatidylethanolamine. It plays roles in membrane homeostasis, lipid signaling, and has been detected in bacteria and mammalian tissues. Dysregulation of this activity is associated with phospholipid accumulation disorders and neurodegeneration. By combining biochemical assays, lipidomics, and CRISPR-based genetic models, researchers can dissect the molecular players and pathways that control this activity. EDITGENE offers comprehensive CRISPR services to support such studies, from knockout to precise point mutations and library screening.
References
- 1. Nagai Y et al.. 1999. An alternative splicing form of phosphatidylserine-specific phospholipase A1 that exhibits lysophosphatidylserine-specific lysophospholipase activity in humans.. J Biol Chem 274(16):11053-9 PMID: 10196188
- 2. Hussain Z et al.. 2017. Mammalian enzymes responsible for the biosynthesis of N-acylethanolamines.. Biochim Biophys Acta Mol Cell Biol Lipids 1862(12):1546-1561 PMID: 28843504
- 3. Fallbrook A et al.. 1999. Phosphatidylcholine and phosphatidylethanolamine metabolites may regulate brain phospholipid catabolism via inhibition of lysophospholipase activity.. Brain Res 834(1-2):207-10 PMID: 10407117
- 4. Yanagihara Y et al.. 1984. Phospholipases of Leptospira. I. Presence of phospholipase A1 and lysophospholipase in Leptospira biflexa.. Microbiol Immunol 28(7):747-56 PMID: 6493072
- 5. Abrar F et al.. 2026. Molecular switches of SQSTM1: the impact of post-translational modifications on autophagy and neurodegeneration.. Autophagy PMID: 42560011
- 6. Weglicki WB et al.. 1987. Phospholipases of the myocardium.. Basic Res Cardiol 82 Suppl 1:107-12 PMID: 3310998
- 7. Kunze H et al.. 1976. Effects of local anaesthetics on phospholipases.. Biochim Biophys Acta 441(1):93-102 PMID: 952985
- 8. Bargal R et al.. 1988. Phospholipids accumulation in mucolipidosis IV cultured fibroblasts.. J Inherit Metab Dis 11(2):144-50 PMID: 3139925
